This episode describes monoclonal antibodies bamlanivimab and casirivimab/imdevimab and the FDA Emergency Use Authorization for these agents. Criteria for use, including patients who are eligible and not eligible for this therapy are discussed, and potential benefits of therapy.  The Regional Infusion Center, a unique collaboration between the Regional Advisory Council, San Antonio Fire and EMS, and local hospitals, is described and discussed.